(Q35855032)

10 August 2017

1 reference

title

New molecular targets for treatment of lymphoma (English)

1 reference

10 August 2017

1

Barbara Pro

0 references

author name string

Barbara Pro

series ordinal

1

1 reference

10 August 2017

Anas Younes

series ordinal

2

1 reference

10 August 2017

publication date

1 September 2004

1 reference

10 August 2017

published in

Current Oncology Reports

1 reference

10 August 2017

volume

6

1 reference

10 August 2017

issue

5

1 reference

10 August 2017

page(s)

360-368

1 reference

Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines.

10 August 2017

cites work

1 reference

12 December 2020

Will mTOR inhibitors make it as cancer drugs?

1 reference

12 December 2020

Mammalian target of rapamycin inhibition as therapy for hematologic malignancies

1 reference

12 December 2020

Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival

1 reference

12 December 2020

To die or not to die--the quest of the TRAIL receptors

1 reference

12 December 2020

Regulation of chemoresistance by the bcl-2 oncoprotein in non-Hodgkin's lymphoma and lymphocytic leukemia cell lines

1 reference

12 December 2020

Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma

1 reference

12 December 2020

1 reference

12 December 2020

CD40 ligand (CD154) and tumour necrosis factor-related apoptosis inducing ligand (Apo-2L) in haematological malignancies

1 reference

12 December 2020

PI3K/Akt signalling pathway and cancer.

1 reference

12 December 2020

Thalidomide for patients with recurrent lymphoma

1 reference

12 December 2020

Analysis of the PI-3-Kinase-PTEN-AKT pathway in human lymphoma and leukemia using a cell line microarray.

1 reference

12 December 2020

Potential for proteasome inhibition in the treatment of cancer

1 reference

12 December 2020

1 reference

12 December 2020

Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells

1 reference

12 December 2020

Signalling pathways of the TNF superfamily: a double-edged sword

1 reference

12 December 2020

Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA)

1 reference

12 December 2020

Increased soluble and platelet-associated CD40 ligand in essential thrombocythemia and reactive thrombocytosis

1 reference

12 December 2020

Re-establishment of a normal apoptotic process as a therapeutic approach in B-CLL.

1 reference

12 December 2020

Elevated levels of biologically active soluble CD40 ligand in the serum of patients with chronic lymphocytic leukaemia

1 reference

12 December 2020

The TNF and TNF receptor superfamilies: integrating mammalian biology

1 reference

12 December 2020

The soluble CD40 ligand sCD154 in systemic lupus erythematosus

1 reference

12 December 2020

Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy

1 reference

12 December 2020

Receptor-mediated choreography of life and death.

1 reference

12 December 2020

Angiogenesis and mast cell density with tryptase activity increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas

1 reference

12 December 2020

Expression of functional CD40 antigen on Reed-Sternberg cells and Hodgkin's disease cell lines

1 reference

12 December 2020

Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL.

1 reference

12 December 2020

Clinical implications of the tumor necrosis factor family in benign and malignant hematologic disorders

1 reference

12 December 2020

The biology of VEGF and its receptors

1 reference

12 December 2020

How the ubiquitin-proteasome system controls transcription

1 reference

12 December 2020

Targeting PI3K-AKT pathway for cancer therapy

1 reference

12 December 2020

Angiogenesis induced by B-cell non-Hodgkin's lymphomas. Lack of correlation with tumor malignancy and immunologic phenotype

1 reference

12 December 2020

Targeting death and decoy receptors of the tumour-necrosis factor superfamily

1 reference

12 December 2020

Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors

1 reference

12 December 2020

Recombinant CD30 ligand and CD40 ligand share common biological activities on Hodgkin and Reed-Sternberg cells

1 reference

12 December 2020

Diagnostic significance of CD40, CD40L, and CD26 expression in Hodgkin's disease and other lymphomas

1 reference

12 December 2020

Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations

1 reference

12 December 2020

Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice

1 reference

12 December 2020

CD40 antigen expression on Reed-Sternberg cells. A reliable diagnostic tool for Hodgkin's disease

1 reference

12 December 2020

BCL-2 antisense therapy in patients with non-Hodgkin lymphoma

1 reference

12 December 2020

Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival

1 reference

12 December 2020

Survival and proliferation factors of normal and malignant plasma cells

1 reference

12 December 2020

Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma

1 reference

12 December 2020

Promising activity of the proteasome inhibitor bortezomib (VELCADE) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma: ASH poster session 517-II.

1 reference

12 December 2020

Promise and problems of Bcl-2 antisense therapy

1 reference

12 December 2020

From angiogenesis to lymphangiogenesis

1 reference

12 December 2020

Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients.

1 reference

12 December 2020

Angiogenesis in B cell lymphoproliferative diseases. Biological and clinical studies

1 reference

12 December 2020

The dynamics of life and death of malignant lymphocytes

1 reference

12 December 2020

Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors

1 reference

12 December 2020

CD30/CD30 ligand and CD40/CD40 ligand in malignant lymphoid disorders

1 reference

12 December 2020

BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone

1 reference

12 December 2020

Targeting mTOR signaling for cancer therapy

1 reference

12 December 2020

10.1007/S11912-004-0062-X

Identifiers

DOI

1 reference

10 August 2017

1 reference